Document is current
Any future updates will be listed below
-
Authors
Patel, Sandip P https://orcid.org/0000-0002-8387-4840
Alonso-Gordoa, Teresa
Banerjee, Susana
Wang, Ding
Naidoo, Jarushka https://orcid.org/0000-0002-3470-8686
Standifer, Nathan E
Palmer, Doug C
Cheng, Lin-Yang
Kourtesis, Panagiotis
Ascierto, Maria L
Das, Mayukh
Diamond, Jennifer R
Hellmann, Matthew D
Carneiro, Benedito A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02671435 at ClinicalTrials.govnct02643550 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
https://doi.org/10.1136/jitc-2022-004569
518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
https://doi.org/10.1136/ijgc-2020-esgo.147
nct04590963 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
nct03822351 at ClinicalTrials.govDocuments that mention this clinical trial
Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial
https://doi.org/10.1136/bmjopen-2024-094596
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
nct05221840 at ClinicalTrials.govDocuments that mention this clinical trial
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
https://doi.org/10.1200/jco.22.00227
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
https://doi.org/10.1136/jitc-2022-004569
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).
https://doi.org/10.1200/jco.2024.42.16_suppl.8046
nct03794544 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
https://doi.org/10.1200/jco.2023.41.16_suppl.tps8610
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
https://doi.org/10.1136/jitc-2024-010316
Documents that mention this clinical trial
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
https://doi.org/10.1136/jitc-2024-009799
-
Funding
Funding for this research was provided by:
AstraZeneca, Gaithersburg, MD., USA (N/A)
- License Information
